These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18080036)

  • 1. The mTOR pathway as a potential target for the development of therapies against neurological disease.
    Zemke D; Azhar S; Majid A
    Drug News Perspect; 2007 Oct; 20(8):495-9. PubMed ID: 18080036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.
    Drakos E; Rassidakis GZ; Medeiros LJ
    Expert Rev Mol Med; 2008 Feb; 10():e4. PubMed ID: 18241520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?
    Corradetti MN; Guan KL
    Oncogene; 2006 Oct; 25(48):6347-60. PubMed ID: 17041621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF-I, EGF, and sex steroids regulate autophagy in bovine mammary epithelial cells via the mTOR pathway.
    Sobolewska A; Gajewska M; Zarzyńska J; Gajkowska B; Motyl T
    Eur J Cell Biol; 2009 Feb; 88(2):117-30. PubMed ID: 19013662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of mTOR in the management of solid tumors: an overview.
    Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
    Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the mTOR signaling network in cancer.
    Chiang GG; Abraham RT
    Trends Mol Med; 2007 Oct; 13(10):433-42. PubMed ID: 17905659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
    Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FRB domain of mTOR: NMR solution structure and inhibitor design.
    Leone M; Crowell KJ; Chen J; Jung D; Chiang GG; Sareth S; Abraham RT; Pellecchia M
    Biochemistry; 2006 Aug; 45(34):10294-302. PubMed ID: 16922504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway.
    Zheng R; Wang L; Fan J; Zhou Q
    Cell Biol Int; 2009 Sep; 33(9):926-33. PubMed ID: 19524688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring mammalian target of rapamycin (mTOR) activity.
    Ikenoue T; Hong S; Inoki K
    Methods Enzymol; 2009; 452():165-80. PubMed ID: 19200882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
    Woodard J; Sassano A; Hay N; Platanias LC
    Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases.
    Chano T; Okabe H; Hulette CM
    Brain Res; 2007 Sep; 1168():97-105. PubMed ID: 17706618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway.
    Kimura R; Okouchi M; Fujioka H; Ichiyanagi A; Ryuge F; Mizuno T; Imaeda K; Okayama N; Kamiya Y; Asai K; Joh T
    Neuroscience; 2009 Sep; 162(4):1212-9. PubMed ID: 19463904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mammalian target of rapamycin pathway and its role in molecular nutrition regulation.
    Lian J; Yan XH; Peng J; Jiang SW
    Mol Nutr Food Res; 2008 Apr; 52(4):393-9. PubMed ID: 18306429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR--beyond transplantation.
    Young DA; Nickerson-Nutter CL
    Curr Opin Pharmacol; 2005 Aug; 5(4):418-23. PubMed ID: 15955739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
    Shuuin T; Karashima H
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A putative mitotic checkpoint dependent on mTOR function controls cell proliferation and survival in ovarian granulosa cells.
    Yaba A; Bianchi V; Borini A; Johnson J
    Reprod Sci; 2008 Feb; 15(2):128-38. PubMed ID: 18276949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
    Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
    Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.